Video

Dr. Logan Discusses Treatment Options in CLL

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia.

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL).

CLL remains the most common leukemia in adults, says Logan. This has led to a lot of innovative therapy, such as monoclonal agents and chemoimmunothearpy.

Additionally, patients with genetic abnormalities such as 17p deletion and p53 now have targeted agents like venetoclax (Venclexta), as these mutations do not respond well to chemoimmunotherapy.

Related Videos
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Ami Umesh Badami, MD
Premal Thaker, MD, MS
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.